MicroRNA-663 Regulates Human Vascular Smooth Muscle Cell Phenotypic Switch and Vascular Neointimal Formation

Pan Li, Ni Zhu, Bing Yi, Nadan Wang, Ming Chen, Xiaohua You, Xianxian Zhao, Charalambos C. Solomides, Yongwen Qin, Jianxin Sun

**Rationale:** Abnormal phenotypic switch of vascular smooth muscle cell (VSMC) is a hallmark of vascular disorders such as atherosclerosis and restenosis after angioplasty. MicroRNAs (miRNAs) have emerged as important regulators for VSMC function, and we recently identified miR-663 as critical for controlling human aortic smooth muscle cell proliferation.

**Objective:** To investigate whether miR-663 plays a role in human VSMC phenotypic switch and the development of neointima formation.

**Methods and Results:** By using quantitative reverse-transcription polymerase chain reaction, we found that miR-663 was significantly downregulated in human aortic VSMCs on platelet-derived growth factor treatment, whereas expression was markedly increased during VSMC differentiation. Furthermore, we demonstrated that overexpression of miR-663 increased expression of VSMC differentiation marker genes, such as smooth muscle α-actin, calponin, and smooth muscle myosin heavy chain, and potently inhibited platelet-derived growth factor–induced VSMC proliferation and migration. We identified the transcription factor JunB and myosin light chain 9 as downstream targets of miR-663 in human VSMCs, because overexpression of miR-663 markedly inhibited expression of JunB and its downstream molecules, such as myosin light chain 9 and matrix metalloproteinase 9. Finally, we showed that adeno-miR-663 markedly suppressed the neointimal lesion formation by ≈50% in mice after vascular injury induced by carotid artery ligation, specifically via decreased JunB expression.

**Conclusions:** These results indicate that miR-663 is a novel modulator of human VSMC phenotypic switch by targeting JunB/myosin light chain 9 expression. These findings suggest that targeting miR-663 or its specific downstream targets in human VSMCs may represent an attractive approach for the treatment of proliferative vascular diseases. (Circ Res. 2013;113:1117-1127.)

**Key Words:** migration ■ miR-663 ■ proliferation ■ vascular remodeling ■ vascular smooth muscle cells

Vascular smooth muscle cells (VSMCs) within the middle layer of the vessel wall perform both contractile and synthetic functions in response to various cellular stimuli. In a cellular process known as phenotype switching, VSMCs alternate between a contractile (also termed differentiated) state and a synthetic phenotype or dedifferentiated state. Dedifferentiated VSMCs have increased rates of proliferation, migration, and synthesis of extracellular matrix components, as well as reduced expression of differentiation markers (ie, smooth muscle α-actin [SMA], smooth muscle 22α [SM22α], smooth muscle myosin heavy chain). Pathological phenotype switching plays a major role in the development of a number of cardiovascular diseases, such as atherosclerosis, postangioplasty restenosis, and hypertension. VSMC phenotype can be dramatically modulated by numerous environmental cues, including growth factor/cytokines, cell–cell contact, cell adhesions, extracellular matrix interactions, mechanical force, and injury stimuli. In particular, platelet-derived growth factor (PDGF) promotes the synthetic VSMC phenotype and increases smooth muscle cell (SMC) proliferation and subsequent migration into the neointima layer after artery injury. However, the molecular mechanisms underlying the SMC phenotypic switch still remains unclear.

**Editorial see p 1102**

In This Issue, see p 1097

Original received March 4, 2013; revision received August 27, 2013; accepted September 6, 2013. In August 2013, the average time from submission to first decision for all original research papers submitted to *Circulation Research* was 12.8 days. From the Center for Translational Medicine (P.L., N.Z., B.Y., N.W., M.C., J.S.) and Department of Pathology, Anatomy, and Cell Biology (C.C.S.), Thomas Jefferson University, Philadelphia, PA; and Department of Cardiology, Changhai Hospital, Second Military Medical University, Shanghai, China (P.L., N.Z., X.Y., X.Z., Y.Q., J.S.).

The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.113.301306/-/DC1.

Correspondence to Jianxin Sun, Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, 1025 Walnut St, Room 408, Philadelphia, PA 19107 (e-mail jianxin.sun@jefferson.edu); or Yongwen Qin, Department of Cardiology, Changhai Hospital, Second Military Medical University, Shanghai, China (e-mail qyw2009@163.com).

© 2013 American Heart Association, Inc.

*Circulation Research* is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.113.301306

1117
MicroRNAs (miRNAs) are a class of conserved, small (approximately 22 nucleotides), single-stranded noncoding RNAs that control diverse biological functions by induction of target mRNA degradation or blockage of translation. Increasing evidence demonstrates that miRNAs regulate a variety of major cellular functions, such as proliferation, migration, and apoptosis; thus, they have been implicated in the development of cardiovascular diseases. Several miRNAs, such as miR-221, miR-222, miR-21, miR-146a, miR-133, miR-143, and miR-145, have been shown to play pivotal roles in the modulation of VSMC function and phenotype switching in animal models. For example, miR-133 and miR-145 are highly expressed in rodent VSMCs; in response to PDGF-BB stimulation, expression is downregulated. Furthermore, knockout studies using mice with miR-133/145 deletion have shown that loss of miR-133 and miR-145 significantly compromises the VSMC contractile phenotype. Importantly, overexpression of miR-145 has been shown to inhibit SMC proliferation and neointima formation after balloon injury by directly repressing the transcription factor KLF5, suggesting that modulation of miRNA expression may have therapeutic potential. Other aspects of PDGF-mediated VSMC phenotype switch is mediated by induction of miR-221. In response to PDGF treatment, the level of mature miR-221 was increased, which in turn leads to increased VSMC proliferation and migration as well as reduced expression of contractile genes, through targeting the cyclin-dependent kinase inhibitors p27Kip1 and p57Kip2. miR-133 has been shown to reduce VSMC proliferation and migration through suppressing the transcription factor Sp-1 expression in rat SMCs. All together, these studies provide significant novel insights into the critical importance and functional complexities of miRNAs in the regulation of VSMC phenotype as well as the development of vascular diseases.

miRNAs are expressed in a tissue-specific manner; thus, VSMCs from different species or tissues may display substantial differences in terms of the expression pattern and functional significance. For example, miR-1 was expressed more in skeletal and cardiac muscle tissue, whereas its expression was almost absent in vascular smooth muscle tissue. Although significant progress has been made in the understanding of VSMC biology regulated by miRNAs in animal models of vascular injury, little is known about the miRNAs that are expressed specifically in human VSMCs. Therefore, clarification of their expression and function would be fundamentally important for understanding the molecular mechanisms involved in human VSMC phenotypic modulation and identification of novel therapeutic targets. In this study, we identified miR-663, whose expression was sharply downregulated in human proliferative VSMCs, as a novel modulator for VMSC phenotypic regulation and neointimal formation in vivo.

Methods

Cell Culture
Human aortic SMCs (Lonza, Walkersville, MD) were cultured in growth media SmGM-2 (Lonza) in 5% fetal bovine serum (FBS), and HEK293 cells were cultured in Dulbecco modified Eagle medium supplemented with 10% FBS.

Oligonucleotide Transfection
For miR-663 overexpression, miR-663 mimic (Qiagen) was added to the complexes at the final concentrations of 10, 20, and 40 nmol/L. For miR-663 knockdown, the miR-663 inhibitor (Qiagen) was added to the complexes at a final concentration of 50 nmol/L. Knockdown of JunB expression was performed using JunB siRNA (Sigma). Cells were transfected using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer’s protocol.

Polymerase Chain Reaction Analysis and RNA Analysis by Quantitative Reverse-Transcription

Western Blot
Western blot analysis was performed as previously described. Briefly, cell lysates were resolved by SDS-PAGE and transferred to nitrocellulose membrane. Blots were blocked with 5% nonfat dry milk in phosphate-buffered saline (PBS) with 0.1% Tween20 and developed to nitrocellulose membrane. Blots were blocked with 5% nonfat milk in phosphate-buffered saline (PBS) with 0.1% Tween20 and developed with diluted antibodies to JunB (1:1000 dilution; Cell Signaling), SM22α (1:300 dilution; Santa Cruz Biotech), SMA (1:800 dilution; Sigma), myosin regulatory light chain 9 (Myl9; 1:1000 dilution; Cell Signaling), and GAPDH (1:1000 dilution; Santa Cruz), followed by incubation with either IRDye 700 or 800 secondary antibodies and visualized using Odyssey Infrared Imaging System software (Li-Cor, Lincoln, NE).

Luciferase Reporter Assay
The fragment of the 3′-UTR of JunB or Myl9 mRNA containing the putative miR-663–binding sequence was cloned into a RenSP luciferase reporter and then cotransfected with vehicle (vehicle control), miR-663 mimic, or a nontargeting mimic control into HEK293 cells according to the instructions provided by Switchgear Genomics. Forty-eight hours after transfection, LightSwitch Luciferase Assay Reagent was added to measure luciferase activity.

Mutagenesis
Two potential miR-663 target sites located at JunB and Myl9 3′-UTRs were mutated using the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA).

Generation of Recombinant Adenovirus
The adenovirus expressing miR-663 (Ad-miR-663) and control viruses expressing green fluorescent protein (Ad-GFP) were used to transduce cells in Dulbecco modified Eagle medium. 

Downloaded from http://circres.ahajournals.org/ by guest on April 20, 2017
SMC Scratch Wound Assay
SMCs were starved in starvation medium (0.5% FBS) for 48 hours. A linear wound was then gently introduced in the center of the cell monolayer using 200 μl tip and then subjected to stimulation with or without human PDGF-BB (Peprotech) at a final concentration of 20 ng/mL and monitored for an additional 24 hours. Images were captured using an Olympus IX 71 microscope equipped with a diagnostic instrument RT SPOT Digital Camera (Canon).

VSMC Proliferation Assay In Vitro
VSMC proliferation in vitro was determined by either MTT assay using Vybrant MTT Cell Proliferation Assay Kit (Invitrogen) or BrdU incorporation assay (Roche Applied Science) according to the protocols provided by manufacturers.

Adventitial Gene Transfer and Carotid Artery Ligation Injury
Briefly, male C57BL/6N mice (20–25 g) were anesthetized with an intraperitoneal injection of avertin (400 mg/kg). The left common carotid artery was ligated with a 6-0 silk suture so that the common carotid artery blood flow was completely disrupted. The common carotid artery was dissected free of the surrounding connective tissue and Ad-miR-663 (1010 pfu/mL) or Ad-LacZ (1010 pfu/mL) was suspended together in 50 μL pluronic F127 gel (BASF Corp; 25% wt/vol) and applied around the carotid artery. Carotid arteries were harvested 2 weeks after ligation. Animals were anesthetized and perfused with 0.9% NaCl, fixed with 4% paraformaldehyde, and embedded in paraffinum. Tissue was sectioned at 6 μm and stained with hematoxylin and eosin and was examined by a light microscope (Nikon); the neointimal area was measured by the computer program ImageJ2x. This study was reviewed and approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University. The use of human tissues was reviewed and approved by the Thomas Jefferson University, and all work with human samples conform the principles outlined in the Declaration of Helsinki.

Immunofluorescence
Briefly, the sections were incubated with anti-PCNA antibodies (1:50 dilution; Cell Signaling), JunB antibody (1:50 dilution; Cell Signaling), and SMA antibody (1:500 dilution; Sigma), respectively, followed by fluorescein-conjugated secondary antibodies (1:300 dilution; Invitrogen). Cell nuclei were stained with DAPI.

In Situ Hybridization of miR-663 in Human Aortic SMC
Human aortic SMCs were fixed in 4% paraformaldehyde, digested with proteinase K (10 μg/mL) for 1 minute, and then postfixed with 4% paraformaldehyde. Slides were prehybridized in hybridization buffer (50% formamide, 5x SSC, 0.1% Tween 20, 50 μg/mL heparin, and 500 μg/mL yeast tRNA) at 55°C for 2 hours and hybridized with hsa-miR-663 probes (LNA mercury probe; Exiqon) at 55°C overnight. Subsequently, antidigoxigenin-POD antibody (Roche) was added and the signals were detected using the tyramide signal amplification system (PerkinElmer).

Statistical Analysis
Data were expressed as mean±SD and analyzed for statistical significance by the unpaired Student t test or ANOVA using SPSS software (version 18.0). P<0.05 was considered statistically significant in all experiments.

Results
Downregulation of miR-663 in Human Proliferative Aortic SMCs
To identify the miRNAs specifically implicated in the regulation of human VSMC function, we performed miRNA microarray in human aortic SMCs after PDGF-BB stimulation for 3, 6, and 24 hours. Results demonstrated that miR-663 was the most downregulated miRNA at all time points (Online Table I). To corroborate these findings, expression of miR-663 was further evaluated in PDGF-induced proliferative human aortic SMCs by quantitative reverse-transcription PCR (qRT-PCR). As shown in Figure 1A and 1B, treatment of human SMCs with PDGF-BB significantly downregulated the expression of miR-663 in a time-dependent and dose-dependent manner. Notably, this inhibitory effect was confirmed by in situ hybridization for miR-663 in PDGF-treated SMCs and quiescent SMCs (Figure 1C). To test the specificity of this response, human aortic SMCs were treated with 5% FBS, another potent stimulant for VSMC proliferation. Similarly, as shown in Figure 1D, miR-663 was rapidly downregulated,

![Figure 1](https://example.com/figure1.png)

**Figure 1. MicroRNA (miR)-663 is significantly downregulated in proliferating vascular smooth muscle cells (VSMCs).** A. Platelet-derived growth factor-BB (PDGF-BB; 20 ng/mL) caused a time-dependent decrease in miR-663 expression in human aortic VSMCs, as determined by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (n=4). *P<0.05 compared with 0 h group. B. PDGF-BB caused a dose-dependent decrease in miR-663 expression in human aortic VSMCs at 24 h after PDGF treatment, as determined by qRT-PCR (n=4). *P<0.05 compared with that in VSMCs without PDGF-BB. C. In situ hybridization (violet) shows miR-663 was significantly decreased in PDGF-BB–stimulated (20 ng/mL) VSMCs. D. Serum (5%) caused a time-dependent decrease in miR-663 expression in human aortic VSMCs, as demonstrated by qRT-PCR (n=4). *P<0.05 compared with that without 5% fetal bovine serum treatment.
with a maximal downregulation of miR-663 expression by ≈90% at 3 hours after FBS stimulation.

To investigate whether miR-663 expression also changes in other types of VSMCs, we examined the expression of miR-663 in human pulmonary artery SMCs (PASMCs). Although basal expression of miR-663 in human PASMCs is ≈3-fold higher than that in human aortic SMCs, we found that miR-663 expression is similarly downregulated in proliferating PASMCs (Online Figure I). Interestingly, the downregulation was also seen in the lung vessels of patients with pulmonary hypertension (Online Figure I), implicating the functional significance of miR-663 in human proliferative vascular diseases.

**miR-663 Is a Novel Phenotypic Marker for VSMCs In Vitro**

To investigate whether miR-663 modulates VSMC phenotype, we examined expression in differentiated SMCs induced by either SMC differentiation medium or all trans retinoic acid (atRA).20,21 Culturing of SMCs in SMC differentiation medium for 48 hours induced differentiation, as indicated by increased expression of VSMC differentiation markers, such as SM22α, SM22α, calponin, and smooth muscle myosin heavy chain, as determined by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (n=5). *P<0.05 compared with SMC growth medium (smGM).

Figure 2. MicroRNA (miR)-663 is upregulated in differentiated human aortic smooth muscle cells (SMCs). A, Vascular SMCs (VSMCs) cultured in SMC differentiation medium (DM) for 48 h caused a significantly increased expression of SMC differentiation marker genes, such as smooth muscle α-actin, smooth muscle 22α, calponin, and smooth muscle myosin heavy chain, as determined by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (n=5). *P<0.05 compared with SMC growth medium (smGM). B, Human aortic SMCs were cultured in SMC differentiation medium to induce SMC differentiation and the expression of miR-663 was measured by qRT-PCR at different time points (n=5). *P<0.05 compared with 0 h group. C, Human aortic SMCs were treated with all trans retinoic acid (atRA; 1 mmol/L) or dimethyl sulfoxide (DMSO) and the expression of SMC differentiation marker genes was determined by qRT-PCR after 72 h of atRA treatment (n=5). *P<0.05 compared with control D, miR-663 was significantly upregulated in atRA-treated SMCs, as determined by qRT-PCR miRNA assay (n=5). *P<0.05 compared with 0 h.

Figure 3. MicroRNA (miR)-663 regulates the expression of vascular smooth muscle cell (VSMC) contractile genes. A, Adenovirus-mediated overexpression of miR-663 (Ad-miR-663) with a multiplicity of infection (MOI) of 100 increases miR-663 levels in a dose-dependent manner (n=4). *P<0.05 vs control viruses expressing green fluorescent protein (Ad-GFP). B, Seventy-two hours after transduction of cell with Ad-miR-663 (MOI=100), the expression of VSMC differentiation marker genes in human aortic SMCs was determined by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (n=5). *P<0.05 compared with Ad-GFP group. C, Ad-miR-663 (MOI=100) increases the expression of SMC differentiation marker genes in human aortic SMCs in the presence and absence of platelet-derived growth factor (PDGF; 20 ng/mL) treatment, as determined by Western blot analysis. D, Densitometric analysis of SMC differentiation marker genes expression as determined by Western blot (n=5). *P<0.05 vs Ad-GFP without PDGF treatment; †P<0.05 vs Ad-GFP with PDGF (20 ng/mL) treatment.
SMA, calponin, and MYH11 (Figure 2A). Accordingly, in a time-dependent manner, the expression of miR-663, as determined by qRT-PCR, was markedly increased after exposure to differentiation medium (Figure 2B). Similarly, atRA markedly induced expression of VSMC differentiation marker genes (Figure 2C), which was accompanied by ≈8-fold increased expression of miR-663 (Figure 2D), after 72 hours of atRA treatment. Together, these findings suggest that miR-663 is important for VSMC phenotypic switch.

**miR-663 Regulates the Expression of Smooth Muscle Marker Genes In Vitro**

To investigate the role of miR-663 in SMC phenotypic switch, we performed gain-of-function studies by using adenovirus-mediated delivery of miR-663 into VSMCs. As shown in Figure 3A, transduction of SMC with Ad-miR-663 resulted in increased expression of miR-663 in a dose-dependent manner. This increase was associated with markedly increased expression of VSMC differentiation marker genes, such as SM22α, SMA, calponin, and MYH11, as determined by qRT-PCR (Figure 3B). Next, we tested whether miR-663 prevents PDGF-BB–induced downregulation of smooth muscle marker genes. As shown in Figure 3C and 3D, overexpression of miR-663 significantly increased the protein levels of SM22α and SMA, as determined by Western blot analysis, under both quiescent and PDGF-stimulated conditions. These results support the notion that miR-663 is a novel modulator for VSMC phenotypic switch.

**miR-663 Is a Novel Regulator of VSMC Proliferation and Migration**

VSMC differentiation is accompanied by decreased proliferation and migration of VSMCs. To determine the potential roles of miR-663 in VSMC proliferation and migration, human aortic SMCs were transfected with miR-663 mimic, anti-miR-663, or negative controls. As shown in Figure 4A, transfection of miR-663 mimics caused a dose-dependent increase of intracellular miR-663 expression, whereas miR-663 inhibitor markedly reduced endogenous levels of miR-663 in VSMCs. Accordingly, transfection of miR-663 mimics significantly inhibited PDGF-BB–induced SMC proliferation, as determined by BrdU incorporation assay (Figure 4B). Furthermore, downregulation of miR-663 expression by anti-miR-663 enhanced SMC proliferation in response to low-dose PDGF-BB (2 ng/mL) (Figure 4C). These findings indicate that miR-663 effectively inhibits human SMC proliferation.

To evaluate the role of miR-663 in SMC migration, we performed the scratch-wound healing assay. As shown in Figure 5A and 5B, adenovirus-mediated overexpression of miR-663 inhibited SMC migration under both quiescent and PDGF-stimulated conditions. In addition, we showed that transfection of SMCs with anti-miR-663 further augmented both basal and PDGF-induced SMC migration (Figure 5C and 5D). Furthermore, MMP-2 and MMP-9, which are implicated in SMC migration, were significantly inhibited by overexpression of miR-663 (Figure 5E). Together, our results indicate that miR-663 is an inhibitor of SMC migration.

**Identification of JunB and Myl9 as Target Genes of miR-663 in VSMCs**

In an attempt to identify targets of miR-663, we used TargetScan and identified JunB as a potential target gene of miR-663 (Online Figure IIA). As shown in Figure 6A, overexpression of miR-663 mimic, but not the control mimics, substantially repressed the activity of luciferase fused with WT-3′-UTR of JunB but had no effect on the luciferase activity, when the miR-663–binding sites in the 3′-UTR of JunB were mutated (Figure 6A), suggesting that miR-663 can directly bind to the 3′-UTR of JunB and regulate its expression.
To further verify that JunB is a functional target gene of miR-663 in VSMCs, we transfected VSMCs with either miR-663 mimic or control mimics, and the levels of JunB expression were determined by Western blot. As shown in Figure 6B and 6C, overexpression of miR-663 significantly inhibited the expression of JunB in VSMCs, under both basal and PDGF-stimulated conditions. Because Myl9 has been identified as a critical downstream target of JunB and implicated in the regulation of SMC migration,23 we attempted to investigate whether miR-663 affects the expression of Myl9. Treatment of SMCs with PDGF markedly increased the expression of Myl9 in VSMCs (Figure 6D). Consistent with the effect of miR-663 on JunB expression, overexpression of miR-663 markedly inhibited the expression of Myl9 under both basal and PDGF-stimulated conditions (Figure 6D).

Targetscan reveals not only JunB as a miR-663 target but also Myl9 with an 8-mer conserved site (Online Figure III). Overexpression of miR-663 mimic markedly inhibited the activity of luciferase fused with 3′-UTR of Myl9 (Figure 6E), indicating that miR-663 may directly affect Myl9 expression. Accordingly, PDGF-induced stress fiber formation was significantly inhibited by miR-663 (Figure 6F). Collectively, these results suggest that miR-663 directly targets both JunB and Myl9 to potently inhibit the JunB/Myl9 pathway in VSMCs.

Figure 5. Role of microRNA (miR)-663 in vascular smooth muscle cell (VSMC) migration. A, Forty-eight hours after transduction of adenovirus-mediated overexpression of miR-663 (Ad-miR-663; MOI=100), VSMCs were starved and cell migration was measured after platelet-derived growth factor (PDGF; 20 ng/mL) stimulation for 24 h by scratch-wound assay. Migrated cells were quantitated and the results are shown in (B). The data are means±SD of the number of migrated cells from 3 independent experiments. *P<0.05 vs control viruses expressing green fluorescent protein (Ad-GFP) without PDGF treatment; †P<0.05 vs Ad-GFP with PDGF treatment. C, Forty-eight hours after transfected with anti-miR-663 (50 nmol/L) or anti-miR control (CTRL) (50 nmol/L), smooth muscle cells (SMCs) were subjected to injury by scraping and then were stimulated with or without PDGF-BB (20 ng/mL) for 24 h. Migrated cells were quantitated using Image J software program and the results are shown in (D). The data are means±SD of the number of migrated cells from 3 independent experiments. *P<0.05 vs CTRL anti-miR without PDGF treatment; †P<0.05 vs CTRL anti-miR with PDGF treatment. E, Ad-miR-663 decreases matrix metalloproteinase 2 (MMP-2) and MMP-9 mRNA levels in human aortic SMCs as measured by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (n=5).

To further verify that JunB is a functional target gene of miR-663 in VSMCs, we transfected VSMCs with either miR-663 mimic or control mimics, and the levels of JunB expression were determined by Western blot. As shown in Figure 6B and 6C, overexpression of miR-663 significantly inhibited the expression of JunB in VSMCs, under both basal and PDGF-stimulated conditions. Because Myl9 has been identified as a critical downstream target of JunB and implicated in the regulation of SMC migration,23 we attempted to investigate whether miR-663 affects the expression of Myl9. Treatment of SMCs with PDGF markedly increased the expression of Myl9 in VSMCs (Figure 6D). Consistent with the effect of miR-663 on JunB expression, overexpression of miR-663 markedly inhibited the expression of Myl9 under both basal and PDGF-stimulated conditions (Figure 6D).

Targetscan reveals not only JunB as a miR-663 target but also Myl9 with an 8-mer conserved site (Online Figure III). Overexpression of miR-663 mimic markedly inhibited the activity of luciferase fused with 3′-UTR of Myl9 (Figure 6E), indicating that miR-663 may directly affect Myl9 expression. Accordingly, PDGF-induced stress fiber formation was significantly inhibited by miR-663 (Figure 6F). Collectively, these results suggest that miR-663 directly targets both JunB and Myl9 to potently inhibit the JunB/Myl9 pathway in VSMCs.

Role of JunB in VSMC Proliferation and Migration
Activation of transcriptional factor AP-1 is implicated in VSMC proliferation and neointimal formation in vivo,24,25 and JunB is the major component of AP-1 complex formed in VSMCs in response to serum and PDGF-BB stimulation.25 To further substantiate the functional significance of JunB in SMC function, we performed loss-of-function study by using JunB siRNA. As shown in Figure 7A, transfection of VSMCs with JunB siRNA significantly inhibited both basal and PDGF-BB–induced JunB expression. Accordingly, JunB knockdown markedly increased the expression of SMC contractile genes such as SM22α and SMA, as determined by Western blot analysis (Figure 7B and 7C). In addition, the PDGF-BB–induced SMC proliferation was significantly inhibited by knockdown of JunB expression (Figure 7D). Likewise, both basal and PDGF-BB–stimulated SMC migration was also markedly attenuated in cells transfected with JunB siRNA (Figure 7E and 7F). To further define the importance of JunB in miR-663–mediated VSMC function, we examined the effect of anti-miR-663 on JunB and Myl9 expression. Transfection of VSMCs with anti-miR-663 significantly increased expression of both JunB and Myl9, whereas knockdown of JunB by specific siRNA in VSMCs markedly attenuated the effect of anti-miR-663 on VSMC proliferation, migration, phenotypic switch, and expression of Myl9 (Online Figure IV). Together, these results suggest that JunB is a critical
miR-663 Inhibits Neointimal Formation in Mice After Carotid Artery Ligation

Although miR-663 is expressed only in human and nonhuman primates, the binding site of miR-663 in JunB 3′-UTR is conserved among different species, such as human, rat, and mouse (Online Figure IIA). Thus, to investigate whether miR-663 inhibits SMC proliferation and migration in VSMCs from other species, we performed studies using mouse SMCs. Similar to findings in human cells, overexpression of miR-663 inhibited the expression of JunB in mouse SMCs (Online Figure IIB). To determine whether miR-663 is involved in vascular lesion formation in vivo, a mouse carotid artery ligation model was used and the neointimal formation was observed in the unligated left common carotid arteries. In contrast, flow cessation led to a substantial increase in neointimal formation in carotid arteries transduced with either gel alone or the gel with Ad-LacZ (Figure 8A). Transduction of carotid arteries with Ad-miR-663, however, substantially inhibited the carotid artery ligation-induced neointimal formation by nearly 60%, which is associated with decreases in both neointimal area (Figure 8B) and the intima-to-media ratio (Figure 8C) in Ad-miR-663–treated arteries. Furthermore, immunofluorescent staining of PCNA, JunB, and SMA was performed in ligated carotid artery. As shown in Figure 8D and 8E, the ratio of PCNA-positive nuclei to total cells was significantly decreased in Ad-miR-663–treated arteries as compared with Ad-LacZ–treated arteries. Moreover, the number of JunB-positive cells was also substantially reduced in Ad-miR-663–treated arteries (Figure 8F and 8G). Taken together, these results suggest that miR-663 inhibits the vascular injury–induced neointimal formation in vivo by suppressing JunB-mediated SMC proliferation.
Discussion

Despite significant progress in our understanding of VSMC biology, the molecular mechanism underlying the human VSMC phenotypic switch still remains elusive. In the present study, we identified miR-663 as a novel modulator implicated in human SMC differentiation, proliferation, and migration. We showed that the expression of miR-663 is markedly downregulated in human proliferative VSMCs and is upregulated in differentiated VSMCs. Both loss-of-function and gain-of-function studies suggest that miR-663 plays a key role in VSMCs phenotypic switch in vitro and in vivo. Furthermore, we demonstrated that miR-663 inhibits VSMC proliferation and migration in vitro and neointimal formation in vivo, most likely through targeting the transcription factor JunB and its downstream targets Myl9 and MMPs.

The functional significance of miR-663 in human diseases has only recently been explored. Accumulating evidence suggests that miR-663 is critically involved in cell growth and differentiation. atRA, as used in the present study to induce SMC differentiation, has been shown to induce the differentiation of acute myeloid leukemia cell line HL-60 by upregulating the miR-663 expression. In human gastric cancer cells, the expression of miR-663 has been shown to be downregulated, and ectopic overexpression of miR-663 represses gastric cancer cell proliferation. Moreover, in vascular endothelial cells, miR-663 expression is increased by oscillatory shear stress and plays a key role in inflammatory response of endothelial cells. Resveratrol (trans-3,4′,5-trihydroxystilbene), a natural antioxidant with cardiovascular and cancer-preventive properties, has been shown to increase miR-663 in colorectal cancer cells and to decrease AP-1 activity in human THP-1 monocytic cells. Because resveratrol has important biological effects in cardiovascular system, it would be interesting to investigate whether miR-663 is involved in resveratrol-induced antiproliferative effects in VSMCs. Nevertheless, at this time, little is known about the role of miR-663 in VSMC biology.

Mechanistically, we identified transcription factor JunB and Myl9 as critical targets of miR-663 in VSMCs. JunB is a major component of the AP-1 complex in VSMCs, and its expression can be significantly induced by multiple stimuli, such as PDGF, FBS, thrombin, and vascular injury. The members of AP-1 family transcription factors, such as Jun, Fos, and ATF proteins, have been implicated in VSMC migration and proliferation in vitro and in vivo. For instance, inhibition of AP-1 by decoy oligodeoxynucleotides has been shown to inhibit VSMC proliferation in vitro and neointimal formation in vivo, further implicating the critical
role of AP-1 in SMC function. In addition, AP-1 has been shown to regulate SMC migration through regulating expression of MMP-9. Importantly, JunB has been recently identified as a key regulator involved in actomyosin-based contractility and motility in VSMCs by targeting Myl9. Myl9 (MLC2), a component of the actomyosin contractile apparatus, has been implicated in actomyosin-based cell contractility and motility. In VSMCs, JunB has been shown to specifically bind to the CRE sites of the Myl9 promoter, thus regulating the expression of Myl9. In JunB-deficient SMCs, the expression of Myl9 was markedly decreased, which led to the impaired stress fiber formation and motility of VSMCs. In VSMCs, JunB has been shown to specifically bind to the CRE sites of the Myl9 promoter, thus regulating the expression of Myl9. In JunB-deficient SMCs, the expression of Myl9 was markedly decreased, which led to the impaired stress fiber formation and motility of VSMCs. In accordance with this observation, we found that overexpression of miR-663 markedly suppressed the PDGF-induced expression of both JunB and Myl9 in VSMCs, hence contributing to its inhibitory effects on VSMC migration. Although miR-663 is expressed exclusively in human and nonhuman primates, the binding site of miR-663 in JunB 3′-UTR is conserved among different species, such as human, rat, and mouse levels, which prompted us to investigate the functional significance of miR-663 in vivo by using mouse carotid artery ligation model. Strikingly, overexpression of miR-663 markedly inhibited the neointimal formation, which is accompanied by decreased expression of JunB and SMC proliferation marker, PCNA. It is worth noting that deficiency of JunB in mesenchyme did not significantly affect vascular remodeling in mouse DOCA-salt model. Although these findings appear to contradict results in our study, it is important to mention that our study focused only on VSMCs, suggesting that JunB may have unique functional roles in different mesenchymal cell types (eg, VSMCs versus vascular endothelial cells). In addition, comparison between studies is complicated by the fact that different vascular injury models were used. Nevertheless, our results are the first to identify miR-663 as a critical modulator in regulating VSMC proliferation and migration, at least in part, through targeting the JunB/Myl9 pathway.

The modulation of VSMC phenotype is of great importance for the resolution of vascular injury. Recent studies have implicated miRNAs, such as miR-143/145, miR-146a, miR-31, miR-221, and miR-133a, as critical targets of multiple growth factor signaling pathways that regulate VSMC phenotype. The molecular mechanisms underlying the regulation of SMC differentiation by these miRNAs are divergent but are mainly involved in the direct or indirect regulation of the expression of transcriptional factors, such as serum response factor, myocardin and myocardin-related transcription factors (MRTFs), and Kruppel-like zinc finger family. In the present study, we examined the effect of miR-663 on these transcriptional factors and found that modulation of miR-663 expression did not significantly affect expression of FOSB, myocardin, MRTF-A, CEBPB, and KLF4, which are the major regulators for expression of SMC.
marker genes (Online Figure VI), suggesting that JunB regulates expression of SMC marker genes, possibly through a mechanism yet to be determined.

In summary, for the first time to our knowledge, we identified miR-663 as a critical regulator in human VSMC differentiation, proliferation, and migration by targeting, at least partly, the JunB/Myl9 pathway. Moreover, the expression of miR-663 was substantially downregulated in pulmonary artery SMCs in patients with pulmonary artery hypertension, indicating a pathologic role of miR-663 in proliferative vascular diseases. Interestingly, JunB deficiency has been recently shown to prevent mice from experiencing development of hypertension and its associated adaptive responses, such as cardiac hypertrophy and retina artery constriction, without a significant effect on the blood pressure at baseline.23 Thus, modulation of JunB/Myl9 expression by miR-663 may have potential as a therapeutic target for treatment of cardiovascular diseases such as atherosclerosis and restenosis.

Acknowledgments

We thank Dr Ross Summer for critical reading of the manuscript and fruitful discussion.

Sources of Funding

This work was supported by the National Institutes of Health (HL103869) and grants from the Chinese Natural Science Foundation (381170114 and 81370418 to J.S., 30971231 to Y.Q., and 81100197 to N.Z.).

Disclosures

None.

References


---

**Novelty and Significance**

**What Is Known?**

- In response to vascular injury, vascular smooth muscle cells (VSMCs) undergo phenotypic switch from the contractile state to the synthetic state.
- Platelet-derived growth factor (PDGF), a key player in occlusive vascular diseases, promotes the synthetic VSMC phenotype and increases VSMC proliferation and migration.
- MicroRNAs (miRNAs) are noncoding small RNAs that play important roles in regulating VSMC function.

**What New Information Does This Article Contribute?**

- Treatment of human VSMCs with PDGF-BB is associated with a reduced level of miR-663.
- Overexpression of miR-663 is associated with increased expression level of the molecular markers of VSMC differentiation and reduced expression level of the transcription factor JunB and myosin light chain 9.
- Targeted overexpression of miR-663 suppresses VSMC proliferation and migration in vitro and reduces vascular injury–induced neointimal formation in vivo.

Understanding molecular mechanisms underlying VSMC phenotypic switch might provide novel therapeutic targets for the treatment of occlusive vascular diseases, such as atherosclerosis and restenosis. We show that miR-663 is highly expressed in human VSMCs and its expression is inversely associated with the proliferation and migration of VSMCs. By targeting a key transcriptional factor, JunB, miR-663 influences VSMC phenotype and neointimal formation. These findings suggest that miR-663 may play an important role in vascular remodeling and could be targeted to develop novel therapeutic strategies.
MicroRNA-663 Regulates Human Vascular Smooth Muscle Cell Phenotypic Switch and Vascular Neointimal Formation
Pan Li, Ni Zhu, Bing Yi, Nadan Wang, Ming Chen, Xiaohua You, Xianxian Zhao, Charalambos C. Solomides, Yongwen Qin and Jianxin Sun

Circ Res. 2013;113:1117-1127; originally published online September 6, 2013; doi: 10.1161/CIRCRESAHA.113.301306

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/113/10/1117

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2013/09/06/CIRCRESAHA.113.301306.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
Supplemental Material

Online Figures
Online Figure I: miR-663 is downregulated in human proliferating pulmonary artery smooth muscle (PASMCs)
Online Figure II: JunB is a target gene of miR-663 in VSMCs
Online Figure III: Alignment of potential binding site for miR-663 in 3’-UTR of Myl9 transcript
Online Figure IV: Knockdown of JunB attenuates anti-miR-663 medicated effect in VSMCs
Online Figure V: Expression of miR-663 and LacZ in mouse left carotid artery after transduction with Ad-miR-663 and Ad-LacZ
Online Figure VI: Effect of miR-663 on the expression of PDGF receptor and transcriptional factors in human VSMCs

Online Tables
Online Table I: miRNA expression in human aortic smooth cells after PDGF treatment
Online Table II: Summary of the real-time PCR Primer sets used

Supplemental Methods

Cell culture
Human aortic SMCs (AoSMCs) (Lonza, Walkersville, MD) were cultured in growth media SmGM-2 (Lonza) in 5% fetal bovine serum at 37°C in a humidified 5% CO2 incubator. All cells used in this study were between passages 5 and 6. HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). In an in vitro differentiation assay, the cells were grown in Medium 231 and smooth muscle differentiation supplement (Invitrogen) for 48 hrs with a daily change of freshly prepared differentiation medium.

**Oligonucleotide transfection**

For miR-663 overexpression, miR-663 mimic (QIAGEN) was added to the complexes at the final concentrations of 10, 20, 40 nM. For miR-663 knockdown, the miR-663 inhibitor (QIAGEN) was added to the complexes at final concentrations of 50 nM. Knockdown of JunB expression was performed using JunB siRNA (Sigma), with Allstars negative siRNA (QIAGEN) as a control. 2 hrs after seeded into the 6 well plates, cells were transfected using HiPerFect Transfection Reagent (QIAGEN) according to the manufacture’s protocol. Transfection medium was replaced by regular cell culture medium after 24 hrs of transfection.

**PCR analysis, RNA analysis by quantitative RT-PCR (qRT-PCR)**

Total RNAs were extracted from human aortic VSMCs and mouse carotid arteries by using either miRNeasy Mini Kit (QIAGEN) or RNeasy kit (QIAGEN).
qRT-PCR for miRNA was performed on cDNA from 20 ng of total RNA by using miRCURY LNA™ Universal cDNA Synthesis kit and SYBR® Green Master Mix Kit (Exqion). PCR analysis of miR-663 was performed using the primers (forward: GAG AGG ATC CTG AGT TTG TGG CTG TG; reverse: GAG TAA GCT TGC AGA CAG GCA AGG G). qRT-PCR for matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), JunB, calponin, SM22α, SM α-actin (SMA), myocardin, myosin heavy chain gene (MYH11) were performed on the cDNAs generated from 250 ng of total RNA by HotStart-IT® SYBR® Green qPCR Master Mix with UDG (2X) Tested User Friendly™ kit (USB Corporation). Primer sequences used for the detection of human MMP-2, MMP-9, JunB, calponin, SM22α, SMA, myocardin, and MYH11 are listed in the Online Table II. The expression of miR-663 relative to U6 and the expression levels of MMP-2, MMP-9, JunB, calponin, SM22α, SMA, myocardin, MYH11 relative to 18S were determined using the $2^{-\Delta\Delta Ct}$ method.

**Western blot**

Cells were lysed into Pierce® RIPA Buffer. After 30 min extraction at 4°C, insoluble material was removed by centrifugation. Cell lyses were then resolved by SDS/PAGE and transferred to nitrocellulose. Blots were blocked with 5% nonfat milk in PBS with 0.1% Tween20 (PBST) and developed with diluted antibodies to JunB (1:1000 dilution; Cat no: 3753S; Cell Signaling), SM22α (1:300 dilution; Santa Cruz Biotech), smooth muscle (SM) α–actin (1:800 dilution; Sigma), Myosin Light Chain 2 (MYL9; 1:1000 dilution; Cat no: 3672P; Cell
Signaling), α-tubulin (1:1000 dilution; Cell Signaling), and GAPDH (1:1000 dilution; Santa Cruz), followed by incubating with either IRDye 700 or 800 secondary antibodies and visualized using Odyssey Infrared Imaging System software (Li-Cor, Lincoln, NE).

**Luciferase reporter assay**

HEK293 cells were seeded in a 96-well plate and transfected at ~80% confluence. The fragment of the 3’-UTR of JunB mRNA containing the putative miR-663 binding sequence was cloned into a RenSP luciferase reporter and then co-transfected with either vehicle (vehicle control), miR-663 mimic, or a non-targeting mimic control into HEK293 cells following the instruction provided by Switchgear Genomics. 48 hrs after transfection, LightSwitch Luciferase Assay Reagent was added to measure luciferase activity.

**Mutagenesis**

Two miR-663 sites located at Jun-B 3’-UTR (site 663-1: CCCCCGCC, starting at nt 300, and site 663-2: CCCCCGCC, starting at nt 346) were mutated to M663-1 (CCGGCGG) and M663-2 (CCGGCGC) using the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). The following primers were used for the mutagenesis of the miR-663 target site-1 in the human JunB 3’-UTR (1st forward: 5’-GGA GCT GGC CGG GCC GCC TGG TAC TC -3’, 1st reverse: 5’-GAG CTG GCC GGC GGG CCT GGT ACT CAA G -3’, 2nd forward: 5’-GAG CTG GCC GGC GGG CCT GGT ACT CAA G -3’, 2nd reverse: 5’-CTT GAG
TAC CAG GCC CGC CGG CCA GCT C-3'); for the mutagenesis of the miR-663 target site-2 in the human JunB-3'-UTR (1st forward: 5'-GGG AAG GGG ACC CGG GCC CCC TGC CCT CC-3', 1st reverse: 5'-GGA GGG CAG GGG GCC CGG GTC CCC TTC CC-3'; 2nd forward: 5'-GGA AGG GGA CCC GGC GCC CCT GCC CTC C-3', 2nd reverse: 5'-GGA GGG CAG GGG CGC CGG GTC CCC TTC C-3').

**Generation of recombinant adenovirus**

The adenovirus expressing miR-663 (Ad-miR-663) and control viruses expression GFP (Ad-GFP) were made using RAPAd® Universal Adenoviral Expression System (CELL BIOLABS, INC) according to the manufacturer's instructions. Briefly, pacAd5 9.2-100 Ad backbone vector was cotransfected with the pacAd5 K-NpA shuttle vector containing the miR-663 sequence into Ad293 cells using FuGene 6 Transfection Reagent (Roche, Indianapolis, IN). The viruses were propagated on Ad293 cells and purified using Cscl2 banding followed by dialysis against 20 mmol/L Tris-buffered saline with 2% glycerol. Titering was performed on Ad293 cells using Adeno-X Rapid Titer kit (Clontech) according to the instructions of the manufacturer. For adenovirus-mediated GFP or miR-663 gene transduction, human aortic SMCs were grown to ~60% confluence and transduced with adenovirus at indicated multiplicity of infection (MOI).

**Smooth muscle cell scratch wound assay**
In gain of function experiment, human aortic SMCs were seeded in 6-well plates at a concentration of $2.5 \times 10^5$ cells per well and transduced with either Ad-miR-663 or Ad-GFP. In loss-of-function experiment, miR-663 inhibitors, JunB siRNA, or their negative controls were transfected with HiPerFect Transfection Reagent (QIAGEN) into SMCs seeded in 6-well plates at a density of $2.5 \times 10^5$ cells per well following the manufacturer’s instructions. After incubation with starvation medium (0.5% FBS) for 48 hr, a linear wound was gently introduced in the center of the cell monolayer using 200 µl tip, followed by washing with PBS to remove the cellular debris. Cells were then subjected to stimulation with or without human PDGF-BB (PEPROTECH) at a final concentration of 20 ng/ml and monitored for additional 24 hr. Photos Images were captured using an Olympus IX 71 microscope equipped with a diagnostic instrument RT SPOT Digital Camera (Canon).

**VSMC proliferation assay in vitro**

VSMC proliferation in vitro was determined by either MTT assay using Vybrant® MTT Cell Proliferation Assay Kit (InvitrogenTM) or BrdU incorporation assay (Roche Applied Science). For MTT assay, SMCs were seeded at $1 \times 10^4$ cells per well in 96-well culture plates for 24 hrs. The cells were transfected with JunB siRNA or negative control siRNA for 24 hrs, and incubated with serum-deprived in 0.5% FBS for 48 hrs. Then MTT labeling reagent was added and incubated for 4 hrs, and solubilized in 0.01N HCl containing 10% SDS for 4 hr. Absorbance was measured at 570 nm on an ELISA plate reader. For BrdU incorporation
assay, BrdU was added to the culture medium for incorporation into cellular DNA. After 4 hrs of incubation, cells were fixed, and anti-BrdU antibody was added and incubated or 30 min. Finally, the absorbance was measured at 405 nm.

**Adventitial gene transfer and carotid artery ligation injury**

Briefly, Male C57BL/6N Mice (20-25g) were anesthetized with an intraperitoneal injection of Avertin (400 mg/kg). The left common carotid artery was ligated with a 6-0 silk suture so that the common carotid artery blood flow was completely disrupted. The common carotid artery was dissected free of the surrounding connective tissue and Ad-miR-663 (10^{10} pfu/ml) or Ad-LacZ (10^{10} pfu/ml) was suspended together in 50µl pluronic F127 gel (BASF, 25%wt/vol) and was applied around the carotid artery. Carotid arteries were harvested 2 weeks after ligation. Animals were anesthetized and perfused with 0.9% NaCl and fixed with 4% paraformaldehyde and embedded in paraffinum. Tissue was sectioned at 6um and stained with hematoxylin/eosin and were examined by a light microscope (Nikon) and the neointimal area was measured by the computer program ImageJ2x. This study was reviewed and approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University.

**Immunofluorescence**

For proliferating cells, the sections were incubated with anti-PCNA antibodies (1:50 dilution; Cell Signaling) followed by fluorescein conjugated secondary antibodies (1:300 dilution; Invitrogen). For JunB staining, the sections were
incubate with JunB antibody (1:50 dilution; Cell Signaling) followed by fluorescein conjugated secondary antibodies (1:300 dilution; Invitrogen). For smooth muscle (SM) α–actin staining, the sections were incubate with smooth muscle (SM) α–actin antibody (1:500 dilution; Sigma) followed by fluorescein conjugated secondary antibodies (1:300 dilution; Invitrogen). Cell nuclei were stained with DAPI.

**In situ hybridization of miR-663 in human aortic SMC**

Human aortic SMCs were seeded into 2 well glass slide chamber and grown to confluence of 60%, then starved in medium containing 0.5% FBS for 48 hrs. Cells were stimulated with PDGF-BB (20 ng/ml) for additional 24 hrs and then fixed in 4% paraformaldehyde. After washed with PBST, slides were digested with proteinase K (10 µg/ml) for 1 min, postfixed with 4% paraformaldehyde and followed by 3 washes in PBST. Slides were pre-hybridized in hybridization buffer (50 % Formamide, 5×SSC, 0.1% Tween-20, 50 µg/ml heparin and 500 µg/ml yeast tRNA) at 55 °C for 2 hrs and hybridized with hsa-miR-663 probes (LNA mercury probe, Exiqon) at 55°C overnight. Then sections were washed in 0.2% SSCT at 55 °C, followed by blocking at room temperature with PBST/5% horse serum for 1 hr. Subsequently, anti-digoxigenin-POD antibody (Roche) was added at dilution of 1:1000 and incubated at room temperature for 1 hr. After post-hybridization washes in PBST, the signals were detected using the tyramide signal amplification system (PerkinElmer). Slides were mounted in Prolong Gold containing DAPI (Invitrogen) and analyzed using a Nikon Eclipse 80i microscope.
equipped with a CCD camera.

**Statistical analysis**

Data were expressed as mean±standard deviation (SD) and analyzed for statistical significance by unpaired Student’s t-test or ANOVA using SPSS software (version 18.0). A p value less than 0.05 is considered statistically significant in all experiments.

---

**Figure I.** miR-663 is downregulated in human proliferating pulmonary artery smooth muscle (PASMCs). (A) Expression of miR-663 in human aortic smooth muscle cells (AoSMCs) and PASMCs as determined by qRT-PCR (n=5). *P<0.05 compared with AoSMC. (B) miR-663 was down-regulated in human PASMCs.
after stimulation with PDGF-BB (20 ng/ml), ET-1 (100 nM), 5-HT (1000 nM), and ANG-II (100 nM) for 24 h, as determined by qRT-PCR (n=4). *P<0.05 compared with CTRL. (C) In situ detection of miR-663 expression in human normal lung vessels and vessels from patients with pulmonary artery hypertension.

![Position 300-306 of JunB 3' UTR (Conserved)](image)

**Position 300-306 of JunB 3' UTR (Conserved)**

<table>
<thead>
<tr>
<th>miR-663 3'-CGCCAGGGGCAGCCCCGGGA-5'</th>
<th>Human</th>
<th>UCGCGCCGGAGCUUGCAGCCCGC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mouse</td>
<td>UCGCGCCGGAGCUUGCAGCCCGC</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>UCGCGCCGGAGCUUGCAGCCCGC</td>
</tr>
</tbody>
</table>

**Position 346-352 of JunB 3' UTR (Poorly conserved)**

<table>
<thead>
<tr>
<th>miR-663 3'-CGCCAGGGGCAGCCCCGGGA-5'</th>
<th>Human</th>
<th>CAUUUGGAAGGGGACGCCCGC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mouse</td>
<td>CAUUUGGAAGGGGACGCCCGC</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>CAUUUGGAAGGGGACGCCCGC</td>
</tr>
</tbody>
</table>

![Position 346-352 of JunB 3' UTR (Poorly conserved)](image)

**Figure II.** JunB is a target gene of miR-663 in VSMCs. (A) Potential binding sites for miR-663 in 3'-UTR of JunB transcript. (B) Overexpression of miR-663 on the expression of JunB in mouse VSMCs as determined by western blot analysis.
Figure III. Alignment of potential binding site for miR-663 in 3'-UTR of Myl9 transcript.

Figure IV: Knockdown of JunB attenuates anti-miR-663 mediated effect in VSMCs. (A) 72 hr after transfection of VSMCs with either CTL siRNA (50 nM), JunB siRNA (50 nM), anti-miR663 (50 nM) or combination of both JunB siRNA (50 nmol/L) and anti-miR663 (50 nM), the expression of JunB and Myl9 were detected by Western blot analysis. Densitometric analysis of JunB and Myl9 expression as determined by western blot (n=3). *$P<0.05$ vs CTL siRNA. #$P<0.05$
vs anti-miR-663; (B) 48 hr after transfection of VSMCs with either CTL siRNA (50 nM), JunB siRNA (50 nM), anti-miR663 (50 nM) or combination of both JunB siRNA (50 nM) and anti-miR663 (50 nM), VSMCs were starved and proliferation rate was analyzed by MTT assay after PDGF (2 ng/ml) stimulation for 24 hr. *P<0.05 vs CTL siRNA; #P<0.05 vs anti-miR-663. (C) 48 hr after transfection of VSMCs with either miR-663 mimic (50 nM), JunB siRNA (50 nM), anti-miR663 (50 nM) or combination of both JunB siRNA (50 nM) and anti-miR663 (50 nM). VSMCs were starved and cell migration was measured after PDGF (20 ng/ml) stimulation for 24 hr by scratch wound assay in the presence of mitomycin C (10 µg/ml). Migrated cells were quantitated. The data are means ± standard deviation of the number of migrated cells from 3 independent experiments. *P<0.05 vs CTL siRNA; #P<0.05 vs anti-miR-663. (D) 48 hr after transfection of VSMCs with either CTL siRNA (50 nM), JunB siRNA (50 nM), anti-miR663 (50 nM) or combination of both JunB siRNA (50 nmol/L) and anti-miR663 (50 nM), the expression of SMA and SM22α mRNA were detected by real-time PCR (n=3). *P<0.05 vs CTRL siRNA; #P<0.05 vs anti-miR-663.
Figure V. Expression of miR-663 and LacZ in mouse left carotid artery after transduction with Ad-miR-663 and LacZ. (A) Ad-miR-663 (10^{10} pfu/ml) or Ad-LacZ (10^{10} pfu/ml) was suspended together in 50 µl pluronic F127 gel (BASF, 25%wt/vol) and was applied around the carotid artery. Carotid arteries were harvested 2 weeks after ligation. Total RNAs were then extracted and subjected to detect the expression of miR-663 by qRT-PCR (n=5). The expression of miR-663 in mouse carotid artery transduced with Ad-LacZ was undetectable (ND). (B) Ad-LacZ (10^{10} pfu/ml) was suspended in 50 µl pluronic F127 gel (BASF, 25%wt/vol) and was applied around the carotid artery. Carotid arteries were harvested 2 weeks after ligation and and sections stained with X-gal and nuclear fast red. Micrographs are representative of sections taken from 8 animals.
Figure VI. Effect of miR-663 on the expression of PDGF receptor and transcriptional factors in human VSMCs. Human aortic VSMCs were transduced with Ad-GFP or Ad-miR-663. 48 hr after transduction, total RNA was extracted and subjected to qRT–PCR analysis to detect the expression of PDGF receptor A and B (A) and transcription factors such as myocardin, MRTF-A, FOSB, CEBPB and KLF-4 (B). (n=3)
# Supplemental data

## Table 1. MiRNA expression in human aortic smooth muscle cell after PDGF-BB treatment

<table>
<thead>
<tr>
<th></th>
<th>Hour</th>
<th>0</th>
<th>3</th>
<th>6</th>
<th>24</th>
<th>Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Down-regulated</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-663</td>
<td>1</td>
<td>0.62</td>
<td>0.23</td>
<td>0.15</td>
<td></td>
<td>5,552</td>
</tr>
<tr>
<td>hsa-miR-638</td>
<td>1</td>
<td>0.60</td>
<td>0.40</td>
<td>0.19</td>
<td></td>
<td>35,390</td>
</tr>
<tr>
<td>hsa-miR-612</td>
<td>1</td>
<td>-</td>
<td>0.07</td>
<td>0.20</td>
<td></td>
<td>664</td>
</tr>
<tr>
<td>hsa-miR-103</td>
<td>1</td>
<td>0.66</td>
<td>-</td>
<td>0.64</td>
<td></td>
<td>5,408</td>
</tr>
<tr>
<td>hsa-miR-107</td>
<td>1</td>
<td>0.70</td>
<td>-</td>
<td>0.66</td>
<td></td>
<td>4,937</td>
</tr>
<tr>
<td>hsa-miR-191</td>
<td>1</td>
<td>0.73</td>
<td>1.3</td>
<td>0.74</td>
<td></td>
<td>7,213</td>
</tr>
<tr>
<td>hsa-miR-181a</td>
<td>1</td>
<td>0.81</td>
<td>-</td>
<td>0.74</td>
<td></td>
<td>5,564</td>
</tr>
<tr>
<td>hsa-miR-214</td>
<td>1</td>
<td>0.78</td>
<td>-</td>
<td>0.74</td>
<td></td>
<td>16,249</td>
</tr>
<tr>
<td><strong>Up-regulated</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-368</td>
<td>1</td>
<td>1.68</td>
<td>-</td>
<td>4.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-376a</td>
<td>1</td>
<td>2.43</td>
<td>-</td>
<td>3.84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-132</td>
<td>1</td>
<td>2.33</td>
<td>-</td>
<td>2.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-29b</td>
<td>1</td>
<td>1.99</td>
<td>-</td>
<td>2.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-30b</td>
<td>1</td>
<td>1.52</td>
<td>-</td>
<td>1.95</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-98</td>
<td>1</td>
<td>1.52</td>
<td>-</td>
<td>1.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-23b</td>
<td>1</td>
<td>1.18</td>
<td>-</td>
<td>1.37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-15a</td>
<td>1</td>
<td>1.87</td>
<td>-</td>
<td>1.88</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-146b</td>
<td>1</td>
<td>1.99</td>
<td>-</td>
<td>1.79</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-27a</td>
<td>1</td>
<td>1.23</td>
<td>-</td>
<td>1.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-222</td>
<td>1</td>
<td>-</td>
<td>1.60</td>
<td>1.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-23a</td>
<td>1</td>
<td>1.16</td>
<td>1.10</td>
<td>1.40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-221</td>
<td>1</td>
<td>-</td>
<td>1.23</td>
<td>1.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-320</td>
<td>1</td>
<td>-</td>
<td>1.68</td>
<td>1.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-125b</td>
<td>1</td>
<td>1.09</td>
<td>1.09</td>
<td>1.19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-199a</td>
<td>1</td>
<td>-</td>
<td>1.09</td>
<td>1.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-24</td>
<td>1</td>
<td>-</td>
<td>1.14</td>
<td>1.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primer</td>
<td>Sequence (5’-3’)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SM α-actin</td>
<td>S: AATGCAGAAGGAGATCACGG&lt;br&gt;             AS: TCCTGTGGCTGATCCACATC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calponin</td>
<td>S: AACCATACACAGGTGAGTC&lt;br&gt;             AS: GATGTCGCGCCCTTCTCTTAG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SM22α</td>
<td>S: TCCAGACTGGACCTCTTTG&lt;br&gt;             AS: TCTTATGCTCCTGCGGTTC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP2</td>
<td>S: ACCCATTACACCTACACCAAG&lt;br&gt;           AS: TGTTGCGAGATCAGGAGTG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP9</td>
<td>S: CGAACCTTGACACGCAGAAG&lt;br&gt;            AS: CACTGAGGAATGATCTAAAGCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardin</td>
<td>S: CCTCACTTTCTGCCCTCATC&lt;br&gt;            AS: GGAATTTAGAAAACTTTGGCCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYH11</td>
<td>S: TGGAACTTCATCGACTTTGGG&lt;br&gt;           AS: ACAGCTTCTCAGCAGAAAGAC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDGFR-A</td>
<td>S: ACAACCACACTCAGACAGAAG&lt;br&gt;           AS: CGTCATTCTAGAGGTACAAAGG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDGFR-B</td>
<td>S: GTCACCACATCATCCTCCTTATC&lt;br&gt;         AS: CTCACAGACTCAATACCTCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRTF-A</td>
<td>S: CTGAAGCAGGAGCTGAAGTT&lt;br&gt;            AS: AGGGCTGATTGGTCTTGATAG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOSB</td>
<td>S: CCTGACGGCTTCTCTCTTTAC&lt;br&gt;           AS: CAGGTTGAGGACAAAAAGGAAGA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEBPB</td>
<td>S: CGCGACAAGGCGCAAGAT&lt;br&gt;              AS: GCTGCTCCACCTTCTTCTG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>